Efficacy of The Turkey Herpes virus-IBDV Vector Vaccine Against Recent Egyptian Very Virulent IBDV in Commercial Layers | ||||
| Journal of Current Veterinary Research | ||||
| Article 6, Volume 2, Issue 1, April 2020, Page 47-56 PDF (949.37 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/jcvr.2020.90223 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
node rade  1; Hesham Sultan2; Alaa Abd El-Razik2
| ||||
| 1department of Birds and rabbits medicine , faculty of veterinary medicine Sadat city university, Sadat city,Egypt | ||||
| 2Department of Birds and Rabbit Medicine, Faculty of Veterinary Medicine, University of Sadat City. | ||||
| Abstract | ||||
| The infectious bursal disease virus (IBDv) is widespread in poultry flocks all around the world. During the period between 2016- 2017, 22 IBD outbreaks were investigated in El-Minoufiya Governorate in different chicken sectors (11 broilers, 7 commercial layer pullets and 4 native baladi varieties). The disease occurred at 23-42 days of age. The mortality ranged between 3-9 % in commercial broilers farms, 5.8-12% in native breed varieties and 5-10 % in commercial layer replacement pullets. Two hundred one-day-old commercial male layer chicks was used for assessment of protection obtained after vaccination with HVT-IBDV vector vaccine "Vaxxitek" against challenged with vvIBDV local field isolate "Lay./Men.Egypt/17" at 46th-day of age. Maternal derived antibodies (MDA) was followed up by ELISA to determine MA waning and the suitable age of chicks for IBDV vaccination and/or challenge. Chicks divided into 4 groups of (50 birds/ of each), G1 (vaccinated with HVT-IBD vector vaccine at 1 day old of age and non-challeneged) and G2 (vaccinated with HVT-IBDV at one-day of age and challenged with vvIBDV local field isolate "Lay./Men.Egypt/017" at 46-day of age), G3 (non- vac-cinated and non-challenged) and G4 (non-vaccinated and challenged chickens). Our results revealed that the mortality percentage of commercial male layer chickens chal-lenged with recent vvIBDV local field isolate "lay./Men.Egypt/017" was (0%) in G2, while in G4 was (90%), at 7-days post challenge. The highest bursa body ratio observed was (5.32 and 5.31) in non- vaccinated and non-challenged birds (G3) and birds vac-cinated with the VAXXITEK HVT-IBDv vaccine (G1). Conclusion, the recombinant VAXXITEK HVT-IBDv vaccine has provided protection for commercial male layer chicks against challenge with recent vvIBDv isolate. Vaccination with vector vaccine in en-demic areas with vvIBDV, protect against mortality, partially against bursal atrophy and decreases immunosuppressive effect of vvIBDV. | ||||
| Keywords | ||||
| HVT-IBD vector vaccine; vvIBDV and Infectious bursal disease (IBD) | ||||
|
Statistics Article View: 292 PDF Download: 511 |
||||
